{"id":782963,"date":"2023-09-11T06:45:38","date_gmt":"2023-09-11T10:45:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/"},"modified":"2023-09-11T06:45:38","modified_gmt":"2023-09-11T10:45:38","slug":"springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/","title":{"rendered":"SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">STAMFORD, Conn., Sept.  11, 2023  (GLOBE NEWSWIRE) &#8212; SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer.\u00a0Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology.<\/p>\n<p>\u201cTai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery into clinical development,\u201d said Saqib Islam, Chief Executive Officer of SpringWorks. \u201cI am delighted to welcome Tai-An to our leadership team and look forward to his contributions as we continue to grow our pipeline on behalf of oncology patients who are in need of transformative new therapies.\u201d<\/p>\n<p>\u201cSpringWorks has a differentiated targeted oncology pipeline and an innovative approach to new program development. I am excited by the opportunity to build on the team\u2019s progress and to advance new programs into the clinic,\u201d said Dr. Lin. \u201cI am also eager to work with the strong leadership team at SpringWorks to reach our collective goal of developing novel therapies that have a meaningful impact on the lives of patients.\u201d<\/p>\n<p>Dr. Lin joins SpringWorks from Black Diamond Therapeutics, where he was Senior Vice President, Translational Science and Discovery Biology. Prior to Black Diamond, Dr. Lin led the translational biomarker research team and Immuno-Oncology precision medicine efforts at EMD Serono. Before EMD Serono, Dr. Lin had extensive experience in leading multidisciplinary drug discovery teams and biology groups at global pharmaceutical companies including Bristol-Myers Squibb, Roche, and Janssen Pharmaceuticals.\u00a0Dr. Lin earned a Ph.D. in Biochemistry from University of Missouri-Columbia and completed postdoctoral research in Molecular Biology and Pharmacology at Washington University in St. Louis.<\/p>\n<p>\n        <strong>About SpringWorks Therapeutics<\/strong>\u00a0<\/p>\n<p>SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks\u2019 strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer. For more information, visit <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u7q4K1o7q3ZhGvTuzBAW2zm2lPsLzt1H_-glRLl-8J7Uk54IXE-gPnUKN45n9HoRUStpRQej9s86HzpDjJd50TNHO7sKDzgwPT8ZLdgGLGM=\" rel=\"nofollow noopener\" target=\"_blank\">www.springworkstx.com<\/a><\/u>\u00a0and follow @SpringWorksTx on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bgVklteIf_0Tus4E23OdKcvrkdduv3-18YMcDkAaR1Xo4YfD804Vn_ILaombUfLASCX8de2ikLFtVJQijEE3FA==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>\u00a0and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XEi42TA9edZY6HWw1Lt9dzZWeGiPTpZVY7OXnDQdqkQRs9IdIDwTmo-FIQgu-IWv0uhql_j8khw3amKfmGzvVNuTy-NRJER-pvXQmWg9Qdca-Ja2vmYTtdLscngrxz4J\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.\u00a0<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\u00a0<\/p>\n<p>\n        <em>This presentation contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, relating to our business, operations, and financial conditions, Words such as, but not limited to, \u201clook forward to,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cwould,\u201d \u201cshould\u201d and \u201ccould,\u201d and similar expressions or words, identify forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks relating to: (i) the success and timing of our product development activities, including the initiation and completion of SpringWorks\u2019 clinical trials, (ii) the fact that topline data or interim data from our clinical studies may not be predictive of the final or more detailed results of such study, or the results of other ongoing or future studies, (iii) the success and timing of our collaboration partners\u2019 ongoing and planned clinical trials, (iv) the timing of our planned regulatory submissions and interactions and the timing and outcome of decisions made by the FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; (v) whether FDA or other regulatory authorities will require additional information or further studies, or may fail or refuse to approve or may delay approval of our drug candidates, including nirogacestat and mirdametinib, (vi) our ability to obtain and maintain regulatory approval of any of our product candidates, (vii) our plans to research, discover and develop additional product candidates, (viii) our ability to enter into collaborations for the development of new product candidates and our ability to realize the benefits expected from such collaborations, (ix) our ability to maintain adequate patent protection and successfully enforce patent claims against third parties, (x) the adequacy of our cash position to fund our operations through any time period indicated herein, (xi) our ability to establish manufacturing capabilities, and our and our collaboration partners\u2019 abilities to manufacture our product candidates and scale production, and (xii) our ability to meet any specific milestones set forth herein.<\/em>\u00a0<\/p>\n<p>\n        <em>Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements.<\/em>\u00a0<\/p>\n<p>\n        <em>For further information regarding the risks, uncertainties and other factors that may cause differences between SpringWorks\u2019 expectations and actual results, you should review the \u201cRisk Factors\u201d in Item 1A of Part II of SpringWorks\u2019 Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, as well as discussions of potential risks, uncertainties and other important factors in SpringWorks\u2019 subsequent filings.<\/em>\n      <\/p>\n<p>\n        <strong>Contacts:<\/strong>\u00a0<br \/>Kim Diamond\u00a0<br \/>Vice President, Communications and Investor Relations\u00a0<br \/>Phone: 203-561-1646\u00a0<br \/>Email: kdiamond@springworkstx.com\u00a0<\/p>\n<p>Samantha Hilson Sandler\u00a0<br \/>Senior Director, Investor Relations\u00a0<br \/>Phone: 203-461-5501\u00a0<br \/>Email: samantha.sandler@springworkstx.com\u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTI4MiM1ODA1ODc0IzIxODQ0ODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2RjZTBiZDAtN2NjNi00OTNlLWE1NWQtYmYwNDc2Mzg5NWY2LTExOTYwMzQ=\/tiny\/SpringWorks-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) &#8212; SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer.\u00a0Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. \u201cTai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery into clinical development,\u201d said Saqib Islam, Chief Executive Officer of SpringWorks. \u201cI am delighted to welcome Tai-An to our leadership team and look forward to his contributions &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-782963","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) &#8212; SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer.\u00a0Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. \u201cTai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery into clinical development,\u201d said Saqib Islam, Chief Executive Officer of SpringWorks. \u201cI am delighted to welcome Tai-An to our leadership team and look forward to his contributions &hellip; Continue reading &quot;SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-11T10:45:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTI4MiM1ODA1ODc0IzIxODQ0ODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer\",\"datePublished\":\"2023-09-11T10:45:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/\"},\"wordCount\":998,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTI4MiM1ODA1ODc0IzIxODQ0ODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/\",\"name\":\"SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTI4MiM1ODA1ODc0IzIxODQ0ODA=\",\"datePublished\":\"2023-09-11T10:45:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTI4MiM1ODA1ODc0IzIxODQ0ODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTI4MiM1ODA1ODc0IzIxODQ0ODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/","og_locale":"en_US","og_type":"article","og_title":"SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer - Market Newsdesk","og_description":"STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) &#8212; SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer.\u00a0Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. \u201cTai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery into clinical development,\u201d said Saqib Islam, Chief Executive Officer of SpringWorks. \u201cI am delighted to welcome Tai-An to our leadership team and look forward to his contributions &hellip; Continue reading \"SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-11T10:45:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTI4MiM1ODA1ODc0IzIxODQ0ODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer","datePublished":"2023-09-11T10:45:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/"},"wordCount":998,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTI4MiM1ODA1ODc0IzIxODQ0ODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/","name":"SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTI4MiM1ODA1ODc0IzIxODQ0ODA=","datePublished":"2023-09-11T10:45:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTI4MiM1ODA1ODc0IzIxODQ0ODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTI4MiM1ODA1ODc0IzIxODQ0ODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=782963"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782963\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=782963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=782963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=782963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}